Navigation Links
Lupus Research Institute strategy delivers $30 million in national funding
Date:11/19/2007

NEW YORK, NY The Lupus Research Institute (LRI) strategy of backing innovative investigations into systemic lupus, the autoimmune disease, has now yielded an unprecedented $30 million in large-scale funding from the National Institutes of Health and other government and private sources, an independent progress report has determined.

To date, 36 scientists have completed their novel research grants from the 7-year-old LRIan Institute investment of $9 million. A remarkable 61% of these investigators have now turned their innovative hypotheses into confirmed discoveries, winning $30 million in large-scale grants to advance new scientific approaches to how and why lupus occurs, and what can be done to prevent and treat it.

The LRI has been the leader in seeking and funding unproven but promising scientific hypotheses in lupus, said Mark Shlomchik, MD, PhD, professor of Laboratory Medicine and Immunology at Yale University School of Medicine and a member of the LRI Scientific Advisory Board. Its because the LRI supported these innovative ideas in the first place that successful competition for scarce federal funding was possible.

An estimated 1.5 million Americans, and millions more worldwide, have lupus. Many are young women in the prime of their lives. No one knows why lupus occurs, or how to prevent or cure it. There hasnt been a new treatment approved for lupus in nearly 50 years, and existing medications are often toxic and can have debilitating effects.

LRI Breakthrough Discoveries in Lupus

Since its inception 7 years ago, the Institute has invested $22 million overall in cutting-edge lupus research, and current LRI-supported investigators are poised to capture similar large-scale awards. The Institute supports scientists from wide-ranging specialties who might otherwise not receive funds for their innovative and untested hypotheses in lupus.

In a brief time, LRI scientists have made break
'/>"/>

Contact: Liane Stegmaier
lstegmaier@lupusny.org
212-812-9881
Lupus Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study identifies genetic risk factor for rheumatoid arthritis, lupus
2. Research shows skeleton to be endocrine organ
3. Newly created cancer stem cells could aid breast cancer research
4. Dominant cholesterol-metabolism ideas challenged by new research
5. Researchers identify proteins involved in new neurodegenerative syndrome
6. Texas researchers and educators head for Antarctica
7. MGH researchers describe new way to identify, evolve novel enzymes
8. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
9. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
10. U of MN researchers discover noninvasive diagnostic tool for brain diseases
11. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore ... key protein linked to stem cell-like behavior in terminal-stage ... drugs that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , ...
... to reduce by more than half the time it takes ... researchers in Penn State,s College of Agricultural Sciences. The finding ... foodborne illness, allowing epidemiological investigators to identify the exact strains ... more quickly find -- and eliminate -- the source of ...
... long been used for various purposes, like cleaning wastewater at ... handcrafted wickerwork, as means of nutrition and, in traditional medicine, ... Fraunhofer Institute for Building Physics IBP in Valley now want ... to wit, for the insulation of outer walls or ...
Cached Biology News:Singapore research team identifies new drug target in deadly form of leukemia 2Researchers develop a faster method to identify Salmonella strains 2Researchers develop a faster method to identify Salmonella strains 3Using cattails for insulation 2Using cattails for insulation 3
(Date:4/23/2015)... April 23, 2015 Delpor, Inc. (Delpor), ... that the United States Patent and Trademark Office has ... NANOPORâ„¢ technology. US Pat. No. 8,986,727 was ... drug delivery device for the sustained release ... technology for the sustained (zero-order) release of large and ...
(Date:4/22/2015)... RICHMOND, Calif. , April 22, 2015  Sangamo ... first quarter 2015 financial results and accomplishments. ... reported a consolidated net loss of $5.3 million, or ... $7.6 million, or $0.12 per share, for the same ... Company had cash, cash equivalents, marketable securities and interest ...
(Date:4/22/2015)... , April 22, 2015   MPIRICA Health ... announced $1.6M in Series A financing from the ... funding helps accelerate consumer and employer awareness of ... surgeries at over 4,800 U.S. hospitals. ... are probably very concerned about choosing the hospital ...
(Date:4/22/2015)... April 22, 2015 Steep Hill, the ... today that it has opened an investment round ... and expansion.  The common stock investment round will ... a law intended to encourage funding of small ... 506(c), small businesses largely relied on friends and ...
Breaking Biology Technology:Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3
... Scientists engaged in biological research and drug discovery are ... BioInformatics, LLC ( www.gene2drug.com ), the premier research ... released preliminary data from the company,s newest report ... Science Suppliers. In this report, we set out ...
... LOUIS, Feb. 11 Sigma-Aldrich, a leading Life,Science and High ... by 6% to $0.68 from $0.64 in the same quarter ... $510 million in the fourth quarter 2008 declined by 4%,compared ... fourth,quarter grew 3% from a year ago. Fourth quarter organic ...
... Development for Chronic Pain IndicationsLA JOLLA, Calif., Feb. ... TPTX ) today announced that oral administration of ... and well-tolerated in healthy male and female subjects ... successful completion of this Phase I trial demonstrating ...
Cached Biology Technology:Life Science Labs Reacting to the Economic Crisis 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 3Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 4Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 5Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 6Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 7Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 8Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 9Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 10Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 11Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 12Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 13First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
... Kinase (PNK) catalyzes the transfer of ... 5'-hydroxyl of single- and double-stranded DNA, ... also removes the 3'-phosphate from 3'-phosphoryl ... 5'-diphosphates to form a 3'-hydroxyl group. ...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Request Info...
... Myeloblastosis Virus Reverse Transcriptase (AMV RT) catalyzes ... RNA or RNA:DNA hybrids (1). It requires ... than RNA primers) as well as Mg2+ ... RNase H activity. Both nonionic detergents and ...
Biology Products: